多组学筛选头颈癌睾丸抗原作为精准免疫肿瘤靶点
该横断面研究对33例头颈部鳞状细胞癌(HNSCC)肿瘤样本(25例初治、8例放疗复发)进行多组学分析,并结合公共转录组数据验证,最终正交验证了23个睾丸限制性和44个睾丸选择性癌睾丸抗原(CTA),其中14个CTA在所有数据集中一致检出,且富集于恶性上皮细胞,提示其作为精准免疫肿瘤靶点的潜力。
要点
- 多组学验证出23个睾丸限制性和44个睾丸选择性CTA在HNSCC中肿瘤特异性表达。
- 14个CTA在所有转录组数据集中一致检出,构成核心候选靶点集。
- CTA在恶性上皮细胞中富集,支持其作为T细胞受体工程等精准免疫治疗靶点。
核心结论
- 在HNSCC中正交验证了23个睾丸限制性和44个睾丸选择性CTA,其中14个CTA在所有数据集中一致检出,具有肿瘤特异性和广泛表达,有望成为精准免疫肿瘤靶点。
研究设计与样本
- 横断面研究,对单中心学术三级医疗中心2018至2023年肿瘤登记库的33例HNSCC肿瘤样本(25例初治、8例放疗复发)进行多组学分析,并使用公共转录组数据集验证。
主要发现
- 33例患者中25例(76%)为男性、8例(24%)为女性,中位年龄61岁(范围29-87岁)。
- 肿瘤亚部位包括口腔24例(73%)、喉7例(21%)、口咽2例(6%);T4a期23例(70%),淋巴结受累16例(48%)。
- 对 institutional bulk RNA 测序数据和外部单细胞RNA测序数据的初步分析鉴定出DKKL1、SPANXB1、SPANXD和ACTL8等CTA在复发肿瘤中上调。
- 扩展再分析显示CTA在HNSCC中广泛表达,包括初治肿瘤;ACTL8免疫组化显示肿瘤组织中等灶性胞质染色。
- 利用正常口腔黏膜单细胞RNA测序数据排除正常组织有任何表达的CTA后,最终列出23个睾丸限制性和44个睾丸选择性HNSCC特异性CTA,其中14个在所有转录组数据集中重叠;CopyKAT分析显示CTA在恶性上皮群体中富集。
临床怎么用
- 本研究鉴定的CTA核心集可作为未来T细胞受体工程等精准免疫治疗开发的候选靶点,但尚未进入临床实践。
局限性
- 研究为单中心横断面设计,样本量33例,需外部更大队列验证;原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignant neoplasm with an increasing need for precision therapeutics. Cancer-testis antigens (CTAs) represent promising targets given their aberrant tumor expression and otherwise localized expression to immune-privileged tissues with no (testis-restricted) or minimal (testis-selective) expression in other human body sites. Despite their potential, limited studies rigorously evaluate CTAs as therapeutic targets in HNSCC. OBJECTIVE: To orthogonally validate and present specific CTAs as potential precision immuno-oncologic targets in both previously untreated (de novo) and recurrent HNSCC tumors. DESIGN, SETTING, AND PARTICIPANTS: This was a cross-sectional study conducting multiomic analyses on a single academic tertiary care center's tumor registry from 2018 to 2023, with validation using publicly available transcriptomic datasets. A total of 33 tumor samples from patients with HNSCC, including both de novo and radiation-recurrent tumors, were analyzed. Data were analyzed from August to December 2024. MAIN OUTCOMES AND MEASURES: The primary outcome was the identification and rigorous validation of specific CTAs with tumor-specific expression in HNSCC. RESULTS: This study analyzed 33 HNSCC institutional tumor specimens, including 25 de novo and 8 radiation-recurrent tumors. Of 33 included patients, 25 (76%) were male, 8 (24%) were female, and the median (range) age was 61 (29-87) years. Tumor subsites included the oral cavity (24 [73%]), larynx (7 [21%]), and oropharynx (2 [6%]). Tumors were primarily T4a (23 [70%]), with nodal involvement in 16 (48%). Initial analysis of bulk RNA-sequenced institutional data and single-cell RNA-sequenced external data identified several CTAs (DKKL1, SPANXB1, SPANXD, and ACTL8) upregulated in recurrent tumors. An expanded reanalysis revealed that CTAs were expressed across HNSCCs, including robust expression not only in radiation-recurrent disease but also in de novo tumors. Immunohistochemistry was performed on ACTL8 to confirm transcriptional level findings at the protein level, which showed moderate focal cytoplasmic staining in tumor tissue. To refine the tumor-specific CTA list, an exclusionary analysis using single-cell RNA-sequenced data from normal oral mucosa was conducted, removing any CTAs with any expression in normal tissue. This resulted in a final list of 23 testis-restricted and 44 testis-selective CTAs specific to HNSCC, of which 14 CTAs overlapped across all transcriptomic datasets. Finally, using CopyKAT, CTAs were specifically enriched in malignant epithelial populations compared with benign populations within the same patients with HNSCC. CONCLUSIONS AND RELEVANCE: In this study, a set of 23 testis-restricted and 44 testis-selective CTAs were orthogonally validated in multiple tumor datasets. Of these, a core set of 14 CTAs were consistently detected across all datasets. Their tumor specificity and broad expression bolster their potential as promising precision immuno-oncologic targets for future T-cell receptor engineering efforts.
引用
- Memon AA, Awan MJ, Espinosa OV, et al. Multiomic Selection of Cancer-Testis Antigens as Precision Immuno-oncologic Targets in Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 41129177. doi:10.1001/jamaoto.2025.3563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。